Immunovant Toekomstige groei
Future criteriumcontroles 2/6
Immunovant zal naar verwachting groeien in winst en omzet met respectievelijk 8.3% en 75.5% per jaar. De winst per aandeel zal naar verwachting groeien met 11.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -175.9% zijn.
Belangrijke informatie
8.3%
Groei van de winst
11.2%
Groei van de winst per aandeel
Biotechs winstgroei | 28.5% |
Inkomstengroei | 75.5% |
Toekomstig rendement op eigen vermogen | -175.9% |
Dekking van analisten | Good |
Laatst bijgewerkt | 20 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Oct 16Immunovant: Switching Lead Candidates Increases Risk
Oct 14We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Jul 18Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive
Jun 27We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Jan 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Nov 06Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Aug 06Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Apr 06We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jun 20Immunovant EPS beats by $0.04
Jun 01argenx rise even as Immunovant pauses the trial for anti-FcRn therapy
Feb 03Immunovant slips 7% on voluntary hold of IMVT-1401 dosing
Feb 02Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management
Jan 14Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?
Dec 30Immunovant (IMVT) Investor Presentation - Slideshow
Nov 16Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2027 | 52 | -547 | -401 | -350 | 11 |
3/31/2026 | 20 | -494 | -441 | -429 | 13 |
3/31/2025 | N/A | -425 | -356 | -348 | 13 |
9/30/2024 | N/A | -323 | -272 | -272 | N/A |
6/30/2024 | N/A | -273 | -244 | -243 | N/A |
3/31/2024 | N/A | -259 | -215 | -214 | N/A |
12/31/2023 | N/A | -243 | -211 | -210 | N/A |
9/30/2023 | N/A | -255 | -210 | -210 | N/A |
6/30/2023 | N/A | -245 | -170 | -170 | N/A |
3/31/2023 | N/A | -211 | -188 | -188 | N/A |
12/31/2022 | N/A | -199 | -166 | -165 | N/A |
9/30/2022 | N/A | -177 | -151 | -151 | N/A |
6/30/2022 | N/A | -167 | -151 | -151 | N/A |
3/31/2022 | N/A | -157 | -106 | -106 | N/A |
12/31/2021 | N/A | -138 | -96 | -96 | N/A |
9/30/2021 | N/A | -128 | -87 | -87 | N/A |
6/30/2021 | N/A | -111 | -91 | -91 | N/A |
3/31/2021 | N/A | -107 | -84 | -83 | N/A |
12/31/2020 | N/A | -100 | -84 | -84 | N/A |
9/30/2020 | N/A | -79 | -66 | -65 | N/A |
6/30/2020 | N/A | -73 | -59 | -59 | N/A |
3/31/2020 | N/A | -66 | -53 | -53 | N/A |
12/31/2019 | N/A | -55 | -43 | -43 | N/A |
9/30/2019 | N/A | -52 | -46 | -46 | N/A |
6/30/2019 | N/A | -44 | -32 | -32 | N/A |
3/31/2019 | N/A | -29 | -29 | -29 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat IMVT de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat IMVT de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat IMVT de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van IMVT ( 75.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van IMVT ( 75.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat IMVT binnen 3 jaar verliesgevend zal zijn.